applsci-logo

Journal Browser

Journal Browser

Recent Advances in Nanocarrier-Based Drug Delivery Systems

A special issue of Applied Sciences (ISSN 2076-3417). This special issue belongs to the section "Biomedical Engineering".

Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 2141

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj 11942, Saudi Arabia
Interests: nanocarrier based drug delivery; solubility; bioavailability
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The research scientists in pharmaceutical industries and research institutions are continuously developing improved drug formulations which could increase the therapeutic benefits and tolerability for the patient. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damage to the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site.

This Special Issue focuses on the recent development of a number of nanocarriers, including nanoparticles, nanoemulsion, liposomes, micelles, dendrimers, meso-porous silica, gold nanoparticles, super-paramagnetic iron-oxide nanoparticles, carbon nanotubes, and quantum dots. These nanocarrier drug delivery systems have the potential to significantly increase the therapeutic efficacy of drugs/molecules while minimizing their toxicity and adverse effects. Furthermore, these systems can be utilized as more intricate systems, alter multiple pathways, or circumvent drug resistance or multidrug resistance mechanisms in various diseases.

Dr. Md. Khalid Anwer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Applied Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nanotechnology, nanocarrier
  • drug delivery, drug targeting

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 3209 KiB  
Article
Development and Characterization of Ibrutinib-Loaded Ethylcellulose-Based Nanosponges: Cytotoxicity Assay against MCF-7 Cell Lines
by Farhat Fatima and Md. Khalid Anwer
Appl. Sci. 2023, 13(8), 4984; https://doi.org/10.3390/app13084984 - 15 Apr 2023
Viewed by 1866
Abstract
Ibrutinib (ITB) is a specific and novel irreversible inhibitor of Bruton’s tyrosine kinase enzyme, for which reason it exhibits potential chemotherapeutic effects against a few types of B-cell cancers. The objective of this study was to design and characterize the targeted anti-cancer moiety [...] Read more.
Ibrutinib (ITB) is a specific and novel irreversible inhibitor of Bruton’s tyrosine kinase enzyme, for which reason it exhibits potential chemotherapeutic effects against a few types of B-cell cancers. The objective of this study was to design and characterize the targeted anti-cancer moiety of ITB encapsulated in polymeric nanosponges (IBNS 1-5). The IBNSs were fabricated using the ultrasonication-assisted solvent evaporation technique. They were optimized for robust nanocarriers by varying the ratio of ethylcellulose (50–200 mg), using a constant amount 50 mg of polyvinyl alcohol ((PVA) stabilizer), and drug ITB. Optimized INBS4 containing 50 mg of ITB, PVA, and 162.5 mg of EC was prepared and was studied for anti-cancer potential. Particle analysis and EE and DL calculation of optimized IBNS4 were 640.9 nm, 0.35, −30.2 mV in size, PDI, and ζp, respectively. Physicochemical characterization (FTIR and DSC) studies of IBNS4 showed that the drug was compatible with excipients, and was encapsulated properly within the core of nanosponges. In vitro drug release studies revealed that IBNS4 followed the Higuchi matrix model with anomalous non-Fickian release kinetics. The in vitro diffusion study of I-NS4 exhibited sustained release for 24 h. Enhanced cytotoxicity effects against the MCF-7 observed with the developed NSs (IBNS4) showed 1.96 times more cytotoxic potential compared to the pure drug (ITB). Full article
(This article belongs to the Special Issue Recent Advances in Nanocarrier-Based Drug Delivery Systems)
Show Figures

Figure 1

Back to TopTop